AbCellera Biologics (NASDAQ:ABCL) Shares Up 8.7% Following Analyst Upgrade

Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) shot up 8.7% on Tuesday after Truist Financial raised their price target on the stock from $12.00 to $30.00. Truist Financial currently has a buy rating on the stock. AbCellera Biologics traded as high as $9.96 and last traded at $10.1520. Approximately 4,091,649 shares traded hands during mid-day trading, a decline of 32% from the average session volume of 5,976,931 shares. The stock had previously closed at $9.34.

A number of other equities research analysts have also issued reports on the stock. Stifel Nicolaus increased their target price on shares of AbCellera Biologics from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Cantor Fitzgerald upped their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Friday, July 17th. Benchmark upgraded AbCellera Biologics from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Tuesday, July 7th. Finally, Wall Street Zen lowered AbCellera Biologics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, AbCellera Biologics currently has a consensus rating of “Moderate Buy” and an average price target of $12.83.

More AbCellera Biologics News

Here are the key news stories impacting AbCellera Biologics this week:

• Positive Sentiment: Strong Phase 2 results provide a major catalyst. ABCL635 delivered positive data in menopausal vasomotor symptoms, improving confidence that the program could advance toward later-stage development and potentially become a commercial product. Analysts and market commentators described the result as AbCellera’s first meaningful pipeline win. AbCellera Biologics Is Up 60.3% After Strong Phase 2 Menopause Data AbCellera Gets Its First Pipeline Win With Positive Phase 2 Data
• Positive Sentiment: Analyst optimism increased. Truist raised its price target from $12 to $30 and maintained a Buy rating, indicating that the clinical data materially changed its valuation outlook. Truist Raises AbCellera Price Target
• Positive Sentiment: Unusually heavy call-option activity signals bullish positioning. Investors purchased substantially more ABCL call options than usual, suggesting traders were positioning for continued volatility or further gains. Options activity, however, does not guarantee sustained demand for the shares. Investors Buy Large Volume of AbCellera Call Options
• Neutral Sentiment: Some commentary views the menopause program favorably but questions whether the results validate AbCellera’s broader antibody-discovery platform, leaving the company’s longer-term growth narrative unsettled. AbCellera: Excellent Phase 2 Data in Menopause but the Platform Narrative Is Fading
• Negative Sentiment: AbCellera proposed a $200 million public offering of shares and pre-funded warrants. The financing strengthens the balance sheet and could fund development, but the new securities may dilute existing shareholders and weigh on the stock after its rally. AbCellera Announces Proposed Public Offering
• Negative Sentiment: One valuation analysis argues the shares could be roughly 33% overvalued following the Phase 2 reaction, highlighting execution, commercialization, and valuation risks. AbCellera Could Be 33% Overvalued Following Phase 2 Results

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. AssuredPartners Investment Advisors LLC acquired a new stake in shares of AbCellera Biologics in the 4th quarter valued at $34,000. Engineers Gate Manager LP acquired a new stake in AbCellera Biologics in the fourth quarter valued at $38,000. Allworth Financial LP lifted its holdings in AbCellera Biologics by 857.0% during the 4th quarter. Allworth Financial LP now owns 11,274 shares of the company’s stock worth $39,000 after buying an additional 10,096 shares during the last quarter. Janney Montgomery Scott LLC purchased a new stake in AbCellera Biologics during the 1st quarter worth about $46,000. Finally, Magnetar Financial LLC acquired a new position in shares of AbCellera Biologics during the 4th quarter worth about $49,000. Institutional investors and hedge funds own 61.42% of the company’s stock.

AbCellera Biologics Trading Up 6.0%

The firm has a market cap of $3.17 billion, a PE ratio of -19.17 and a beta of 1.20. The business has a fifty day moving average price of $6.45 and a 200 day moving average price of $4.81.

AbCellera Biologics (NASDAQ:ABCL) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.18) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.02). AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. The company had revenue of $4.05 million during the quarter, compared to analysts’ expectations of $7.85 million. On average, research analysts expect that AbCellera Biologics Inc. will post -0.68 earnings per share for the current fiscal year.

AbCellera Biologics Company Profile

AbCellera Biologics Inc (NASDAQ: ABCL) is a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s technology platform integrates single-cell screening, microfluidics, high-throughput sequencing and artificial intelligence to rapidly identify and optimize antibody candidates against a wide range of disease targets. By combining experimental data with machine learning, AbCellera accelerates early-stage drug discovery and improves the efficiency of lead candidate selection.

AbCellera primarily operates through partnerships with pharmaceutical and biotechnology firms, offering its antibody discovery services on a fee-for-service and milestone-driven basis.